Pharmacokinetics, Safety and Efficacy of Intravenous Vedolizumab in Paediatric Patients with Ulcerative Colitis or Crohn’s Disease: Results from the Phase 2 HUBBLE Study - Concepedia

Concepedia

Publication | Open Access

Pharmacokinetics, Safety and Efficacy of Intravenous Vedolizumab in Paediatric Patients with Ulcerative Colitis or Crohn’s Disease: Results from the Phase 2 HUBBLE Study

DOI Full Paper Access

42

Citations

16

References

2022

Year

Jeffrey S. Hyams, Dan Turner, Stanley A. Cohen, Erzsébet Szakos, Kinga Kowalska‐Duplaga, Frank M. Ruemmele, Nicholas M. Croft, Bartosz Korczowski, Promise Lawrence, Siddharth Bhatia,

Journal of Crohn s and Colitis

Abstract

Vedolizumab exposure increased in an approximate dose-proportional manner. No clear dose-response relationship was observed in this limited cohort. No new safety signals were identified.

References

	Year	Citations

Page 1